FPI-2265 (225Ac-PSMA-I&T)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for FPI-2265 (225Ac-PSMA-I&T), covering 2026-04-08 to 2026-04-08. Get the full timeline:
Most recent: Clinical Trial Update: FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 2]